Testosterone laboratory testing and measurement (coverage criteria)
Customize your policy alerts
Sign up for all Premera Bluecross policy alerts
Know when Premera Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
Defines when serum total, free, bioavailable testosterone and related hormone tests (e.g., SHBG, albumin, estradiol, DHT) are reimbursable, not reimbursable, and provides analytical/testing guidance; applies to Premera Bluecross coverage determinations.
Corrected policy statements to indicate measurement of serum free testosterone and/or bioavailable testosterone as a primary test and for asymptomatic individuals or those with non-specific symptoms is not reimbursable.
Coverage Criteria for Testosterone and Related Tests
inv-01: Covered: Total testosterone and related tests
Measurement of serum total testosterone is reimbursable when any one of the following applies:
Direct from Indications 1.a; includes monitoring intervals and repeat-testing guidance
Direct from Indications 5
Direct from Indications 4
inv-02: Covered: Supplemental testing
Additional reimbursable testing when specified conditions exist:
Direct from Indications 2
Direct from Indications 3; calculated fT or bioavailable assays preferred over direct immunoassays
inv-03: Not medically necessary / Not reimbursable
Tests or situations considered not reimbursable:
Direct from Indications 6
Direct from Indications 7
Direct from Indications 8
Direct from Indications 9
inv-04: Guideline-based coverage criteria
Covered when recommendations from specialty societies are followed (examples below):
Includes recommendation to measure LH/FSH to distinguish primary vs secondary hypogonadism and evaluate for reversible causes; based on ES, AUA, CUA/CSAM, EAA guidance
Society recommendations call for documenting baseline values for monitoring
Based on ES, CUA/CSAM, and transgender care guidance (Hembree et al.)
Explicit technical comment from ES and reiterated by EAA and others
inv-05: Diagnostic testing criteria
Testing and confirmation of hypogonadism is supported when following these diagnostic steps:
Confirmatory testing for suspected hypogonadism
- Timing: Collect samples between 7 AM and 11 AM or within 3 hours after waking for shift workers.7–11 AM (or within 3 hours of waking)
CUA/CSAM and other societies specify sampling window
- Supplemental hormone measurements: Measure LH and prolactin to characterize gonadal status; consider measuring SHBG and calculating free or bioavailable testosterone when SHBG-altering conditions exist or total T is borderline (~8–12 nmol/L); measure FSH when assessing spermatogenesis or infertility; measure estradiol only in specific scenarios when validated mass spectrometry is available.clinical indication-dependent
EAA, EAU, CUA/CSAM guidance
AAP Choosing Wisely guidance
inv-06: ADT monitoring
Monitoring for patients on androgen deprivation therapy (ADT):
NCCN guidance for castrate-level documentation and monitoring intervals
inv-07: Coverage summary
Covered when ALL of the following are met (policy-level summary):
Policy-level summary referencing coverage statements and documentation expectations
Corrected policy statement effective for dates of service on or after September 4, 2026
The policy excludes use of saliva specimens for testosterone measurement from reimbursement. Additionally, measurement of serum dihydrotestosterone (DHT) is not reimbursable except when ordered for the specific, listed indications in this policy. Claims for salivary testosterone testing or for serum DHT outside the specified diagnostic uses may be denied.
Direct analog-based immunoassays and commercially available kits that report direct free testosterone (fT) are specifically discouraged due to poor accuracy and reliability. When free testosterone assessment is required, clinicians should prefer calculated fT based on total testosterone, SHBG, and albumin or measure fT by equilibrium dialysis rather than using direct immunoassays.
For children with only pubic hair or body odor and no other signs of puberty, routine ordering of LH/FSH together with estradiol or testosterone is discouraged. Premature adrenarche is usually benign and does not require activation of the hypothalamic–pituitary–gonadal axis evaluation; such hormone panels in isolated adrenarche may be inappropriate and are not recommended.
Measurement of serum free testosterone and/or bioavailable testosterone as a primary test (i.e., without a prior serum total testosterone) is not reimbursable. The corrected policy statement clarifies that claims for primary use of free or bioavailable testosterone testing, or testing for asymptomatic individuals or those with non-specific symptoms, are not covered effective for dates of service on or after September 4, 2026.
The policy excludes primary testing with free or bioavailable testosterone, testing performed in asymptomatic individuals or for non-specific symptoms, and salivary testosterone testing from reimbursement. These uses are considered not medically necessary due to insufficient evidence of clinical benefit.
Major specialty guidance advises against routine population screening for hypogonadism. The European Society (ES) recommends diagnosing hypogonadism only in symptomatic men with consistently low total (and when indicated, free) testosterone and advises against routine screening of the general male population. ACOG likewise recommends against routine monitoring of serum androgens in adolescents with hyperandrogenism and does not support routine population screening.
The European Academy of Andrology (EAA) does not recommend routine measurement of serum estradiol. Estradiol testing is suggested only when a validated mass spectrometry–based method is available or in rare cases of suspected severe estrogen deficiency.
Use of free and/or bioavailable testosterone assays as the primary diagnostic test in lieu of total testosterone, and testing in asymptomatic individuals or those with non-specific symptoms, are not reimbursable. Total testosterone measured on appropriately timed morning samples remains the preferred initial test; supplemental free/bioavailable testing is covered only when criteria in this policy are met.
Coding and Laboratory Test Standards
| 82040 | Albumin; serum, plasma or whole blood |
| 82642 | Dihydrotestosterone (DHT) |
| 82670 | Estradiol; total |
| 82681 | Estradiol; free, direct measurement (e.g., equilibrium dialysis) |
| 84270 | Sex hormone binding globulin (SHBG) |
| 84402 | Testosterone; free |
| 84403 | Testosterone; total |
| 84410 | Testosterone; bioavailable, direct measurement (e.g., differential precipitation) |
| No codes listed |
Provider Responsibilities, Documentation, and Billing Guidance
Pre-therapy laboratory prerequisites
Obtain baseline PSA in men over age 40 and measure hemoglobin/hematocrit prior to initiating testosterone therapy; these baseline labs support safe initiation and monitoring of therapy.
- PSA: measure prior to therapy in men >40 (AUA/Endocrine Society guidance referenced).
- Hematocrit/hemoglobin: obtain baseline prior to initiating testosterone replacement.
ADT monitoring documentation
For patients on androgen deprivation therapy, document castrate serum testosterone (<50 ng/dL) when clinically indicated and monitor PSA and testosterone at the recommended intervals.
- Maintain documentation of castrate level (<50 ng/dL).
- Monitor PSA and testosterone every 3–6 months per NCCN guidance.
Prior authorization
The policy text does not specify any formal payer prior authorization requirements or prior authorization codes for testosterone or related hormone testing.
- No explicit prior authorization rules are provided in the policy excerpt.
Testing sequence preference
Use serum total testosterone as the initial laboratory evaluation; free or bioavailable testosterone testing is reimbursable only when indicated (e.g., low/borderline total T or suspected SHBG perturbation).
- Initial evaluation: total testosterone first (morning, fasting samples).
- Free/bioavailable tests reimbursable as supplemental testing when clinical criteria met.
Sequential testing preference
If total testosterone is near the lower limit or conditions affecting SHBG are present, proceed to calculated free testosterone using total T, SHBG, and albumin or use equilibrium dialysis rather than direct immunoassays.
- Calculated free T based on TT, SHBG, and albumin or equilibrium dialysis is preferred.
- Avoid direct analog-based free testosterone immunoassays for this purpose.
Follow guideline-based testing algorithms
Providers should follow documented clinical indications and specimen/assay guidance when ordering tests to support coverage decisions.
- Ensure orders align with guideline-based indications and testing algorithms.
Step therapy
No step therapy requirements are specified by the policy for testosterone or related hormone testing.
- Policy explicitly states no step therapy requirements in this section.
Specimen timing and assay certification
Document symptom-based indications and, when applicable, prior total testosterone results; use CDC HoSt–certified or validated assays for total testosterone measurement.
- Record the clinical signs/symptoms prompting testing.
- When available, use assays certified by the CDC HoSt/Testosterone program (±6.4% standardization).
Required baseline and follow-up documentation
When diagnosing hypogonadism, document two separate early-morning total testosterone measurements and baseline hematocrit/hemoglobin prior to initiating therapy.
- Two morning TT measurements at least 24 hours apart (repeat testing no sooner than 60 days if initial normal but symptoms persist).
- Record baseline testosterone and hematocrit/hemoglobin before starting treatment.
Record sample timing
Record the time of morning serum collection (samples should be collected between 7 AM and 11 AM or within 3 hours after waking for shift workers) to support interpretation.
- Document exact collection time to verify it falls within the recommended window.
Documentation of indication
Document the specific clinical indication or criteria that justify ordering testosterone or related hormone testing to support reimbursement in accordance with policy coverage statements.
- Include symptom/sign details or guideline-based indication on the order or in the chart.
Denial triggers for unsupported indications
Ordering free or bioavailable testosterone as the primary test without a prior total testosterone measurement is not reimbursable, and testing in asymptomatic individuals or for non-specific symptoms is deniable.
- Claims for primary free/bioavailable testing without prior total T risk denial.
- Testing for asymptomatic individuals or nonspecific symptoms is not reimbursable.
Accurate assay and measurement practice
Do not use direct analog-based free testosterone immunoassays due to inaccuracy; prefer serum total testosterone measured on two separate mornings and calculate free testosterone using validated algorithms or use equilibrium dialysis when indicated.
- Direct free-T immunoassays are discouraged; use calculated free T (TT, SHBG, albumin) or equilibrium dialysis.
- Total T should be measured twice on morning samples using validated/standardized assays.
Avoid unnecessary hormone panels in isolated adrenarche
Avoid ordering LH/FSH with estradiol or testosterone for children who present only with pubic hair or body odor and no other signs of puberty, as premature adrenarche is usually benign.
- Such hormone panels in isolated adrenarche are discouraged and may be considered inappropriate.
Non-reimbursable primary/broad testing
Measurement of serum free testosterone and/or bioavailable testosterone as a primary test and testing in asymptomatic individuals or those with non-specific symptoms is not reimbursable and claims for these uses may be denied.
- Free/bioavailable tests as primary diagnostics are non-reimbursable.
- Testing in asymptomatic or nonspecific-symptom individuals is non-reimbursable.
Background and Clinical Context
Testosterone is produced by Leydig cells in the testes in males and by the ovaries and adrenal glands in females and is central to sexual development, maintenance of secondary sexual characteristics, spermatogenesis, and conversion to dihydrotestosterone and estradiol. Disorders of testosterone production or action underlie conditions such as hypogonadism and polycystic ovary syndrome; measurement and interpretation of testosterone require attention to specimen timing, assay method, and clinical context.
Key Definitions and Laboratory Methods
Policy Revision History
Corrected policy statements to specify that measurement of serum free testosterone and/or bioavailable testosterone as a primary test and for asymptomatic individuals or those with non-specific symptoms is not reimbursable; effective for dates of service on or after September 4, 2026 following 90-day provider notification.
New policy on routine testosterone testing became effective for dates of service on or after February 6, 2026 after 90-day provider notification; measurement of serum total testosterone may be considered reimbursable for indications outlined in the policy when criteria are met.
Policy created and approved October 14, 2025 (recorded 11/01/25) as a new policy and added to Routine Test Management section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.